Idelalisib in the management of lymphoma

Chan Y. Cheah, N.H. Fowler

Research output: Contribution to journalArticlepeer-review

98 Citations (Scopus)


© 2016 by The American Society of Hematology.Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3Kδ inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide a brief summary of the preclinical data, and describe the clinical experience with this agent in patients with lymphoma. We describe some of the idiosyncratic toxicities of this agent, some of the mechanisms of resistance, and some of the ongoing combination strategies.
Original languageEnglish
Pages (from-to)331-336
Number of pages6
Issue number3
Publication statusPublished - 21 Jul 2016


Dive into the research topics of 'Idelalisib in the management of lymphoma'. Together they form a unique fingerprint.

Cite this